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Summary  
The finding that dendritic cells (DCs) orchestrate innate and adaptive immune responses has 
stimulated research on harnessing DCs for developing more effective vaccines for DC 
therapy. The expression of cytomegalovirus (CMV) antigens in glioblastoma multiforme 
(GBM) presents a unique opportunity to target these viral proteins for tumor immunotherapy. 
Here, we demonstrate that Vγ9γδT cells, innate immune cells activated by zoledronate (Z), 
and Vα24NKT cells, innate/adaptive immune cells activated by α-galactosylceramide (G) can 
link innate and adaptive immunities through cross talk with IFN-DCs from patients with 
GBM and healthy donors in a way that can amplify the activation and proliferation of 
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CMVpp65-specific CD8+T cells. The IFN-DCs derived from patients with GBM used in this 
study express lower levels of programmed death ligand (PDL)1 and PDL2 and higher levels 
of CCR7 than the most commonly used mature IL-4DCs. The expression level of 
programmed cell death 1 (PD1) on CD8+ T cells, including CMVpp65-specific CD8+T cells, 
expanded by IFN-DCs pulsed with the CMVpp65-peptide and Z plus G (IFN-DCs/P+Z+G) 
was lower than that expanded by IFN-DCs pulsed with the peptide alone (IFN-DCs/P). 
Multifunctional T cells, including HLA-A*0201-restricted CMVpp65-specific CD8+T cells, 
Vγ9γδT cells, and Vα24NKT cells, efficiently kill HLA-A*0201 positive GBM cell line 
expressing CMVpp65 protein (T98G). These findings indicate that DC therapy using 
IFN-DCs/P+Z+G and/or CTL therapy using CMVpp65-specific CD8+T cells expanded by 
IFN-DCs/P+Z+G may lead to a good clinical outcome for patients with GBM.  
Introduction 
Dendritic cells (DCs) are central players in the immune system and operate at the interface of 
innate and adaptive immunities. DCs have attracted much interest over the past decades for 
their use in therapeutic vaccination against cancer owing to their professional antigen-specific 
T cell immunity. Clinical trials have shown that the use of tumor antigen-loaded DCs in 
cancer patients (Pts) is safe; however, their potential in inducing antitumor immunity to 
eradicate tumors is seen in only a minority of patients [1, 2]. This underscores the necessity to 
redesign and optimize current procedures for DC vaccine manufacture.  
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   For DC therapy that successfully eradicates tumors, it is crucial to marshal and 
orchestrate a vast array of effector cells, including adaptive immune cells such as tumor 
antigen-specific CD8+T and CD4+helper T cells, innate immune cells such as γδT and NK 
cell, and innate/adaptive immune cells, Vα24NKT cells [3], in which DCs play a pivotal role 
in bridging innate and adaptive immunities. Our clinical study using DCs pulsed with 
α-galactosylceramide (G), which is a ligand of Vα24NKT cells for Pts with melanoma, has 
demonstrated that the Vα24NKT cells activated by G-pulsed DCs did bridge innate and 
adaptive immunities to induce the activation and proliferation of IFNγ-producing CD8+T 
cells following the activation of Vα24NKT and NK cells in vivo [4]. Furthermore, an in vitro 
study has shown that the induction of tumor antigen-specific CD8+T cells was amplified by 
DCs pulsed with a tumor antigen and zoledronate (Z), in which Vγ9γδT cells expanded by Z 
function as helper T cells through the production of Th1 cytokines such as IFNγ and TNFα [5, 
6]. 
  In this study, we aimed for a much stronger induction of tumor antigen-specific CD8+T 
cells. We speculated that DCs pulsed with a tumor antigen and Z plus G may enhance the 
induction of tumor antigen-specific CD8+T cells through further expansion of not only 
Vγ9γδT cells but also Vα24NKT cells.  
The outcome of DC therapy depends on the characteristics of DCs infused. The most 
widely adopted method of generating DCs of clinical use involves a one-week, two-step in 
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vitro culture. It requires incubation of monocytes with IL-4 and 
granulocyte/machrophage-colony stimulating factor (GM-CSF) to obtain immature IL-4 
-induced DCs (IL-4DCs), followed by treatment with different maturation stimuli to obtain 
various mature IL-4-induced DCs (mIL-4DCs) [7, 8].  In another method of DC preparation, 
it has been shown that monocytes cultured with GM-CSF plus IFN-α can be induced toward 
the DC lineage, so-called IFN-DCs, which highly express CD56 and CD14 molecules [9-11]. 
Our previous in vitro study has shown that CD56
high+
IFN-DCs possessing HLA-A*0201 
effectively induce Mart1-modified melanoma peptide (A27L)-specific CD8+T cells in the 
presence of A27L and Z through preferential expansion of CD56+ Vγ9γδT cells, which are 
potent antitumor effectors more capable of killing tumor cells than CD56- Vγ9γδT cells [12]. 
Taken together with these previous studies of DCs, Vγ9γδT cells, and Vα24NKT cells, we 
highly expected that IFN-DCs pulsed with a tumor antigen and Z plus G enhance the 
induction of tumor antigen-specific CD8+T cells through the expansion of Vγ9γδT and 
Vα24NKT cells in vitro. Then, infusion of IFN-DCs pulsed with a tumor antigen and Z plus 
G results in a better clinical outcome through the effective expansion of tumor 
antigen-specific CD8+T cells in vivo, in which Vγ9γδT and Vα24NKT cells function as 
adjuvants to enhance the expansion of tumor antigen-specific CD8+T cells. 
Despite aggressive surgery, radiation, and chemotherapy, treatment of patients with 
glioblastoma multiforme (GBM) is rarely curative, and conventional therapies are inherently 
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nonspecific and damage surrounding normal tissues [13, 14]. Immunotherapies including DC 
therapy provide a promising alternative owing to the intrinsic specificity and potentially 
long-lasting effects of immune activation [15]. In this study, we chose pp65, an antigen from 
a common herpes virus called CMVpp65, in GBM as the tumor antigen [16]. Importantly, the 
CMV antigens have been detected in cancellous areas of histological sections but not in 
surrounding healthy tissues [17, 18].  
  Recently, various molecules that can modulate TCR signals have been identified. Multiple 
costimulatory and inhibitory interactions regulate T cell responses to antigen-presenting cells 
(APCs) such as DCs [19-21]. Many ligands bind to multiple receptors, some of which deliver 
costimulatory signals and others deliver inhibitory signals. In this study, we focused on the 
expression levels of programmed death ligand (PDL)1 and PDL2 on IFN-DCs as well as the 
expression levels of PD1 and cytotoxic T lymphocyte antigen (CTLA)4 on CD8+T cells, 
which are expanded by IFN-DCs pulsed with the CMVpp65-peptide alone (IFN-DCs/P) and 
compared them with those on CD8+T cells, which are expanded by IFN-DCs pulsed with the 
peptide and Z plus G (IFN-DCs/P+Z+G). 
Immunoinhibition renders T cells dysfunctional in the tumor microenvironment (TME), in 
which different immunosuppressive cell populations such as regulatory T cells (Treg cells) 
and myeloid-derived suppressor cells are involved [22].  In this study, we also examined the 
induction of CD4+CD25+FoxP3+Treg cells [23] by IFN-DCs/P vs IFN-DCs/P+Z+G. 
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Human CMV (HCMV) is a ubiquitous opportunistic pathogen. Symptomatic HCMV 
infection predominantly occurs in immunocompromised hosts, such as patients after 
allogeneic hematopoietic stem cell transplantation (alloSCT), whereas symptomatic infection 
of healthy donors (HDs) is rare. Although inapparent CMV viremia as a potential prestage of 
a manifest CMV system or an organ disease can be detected as early as 10 to 14 days after 
alloSCT and may last for several weeks but usually resolves after an early preemptive 
treatment with nucleoside antiviral agents such as ganciclovir [24], it is conceivable that 
infusions of CMV-specific CD8+T cells from allogenic HDs may decrease relapse risk in the 
patients who had alloSCT.  Thus, we also analyzed the ability of HD-derived 
IFN-DCs/P+Z+G. 
The aims of this study were as follows: 
1. To determine whether IFN-DCs/P+Z+G derived from GBM Pts can most extensively 
induce CMVpp65-specific CD8+T cells, as well as expanded V9T and V24NKT cells, as 
compared with IFN-DCs/P, IFN-DCs/P+Z, or IFN-DCs/P+G. 
2. To assess whether the expression level of PD1 on CD8+T cells including 
CMVpp65-specific CD8+T cells expanded by IFN-DCs/P+Z+G is lower than that on the 
CD8+T cell expanded IFN-DCs/P.  
3. To determine whether effector cells including HLA-A*0201-restricted CMVpp65-specific 
CD8+T, Vγ9γδT, and Vα24NKT cells efficiently kill HLA-A*0201 positive T98G cell line 
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expressing CMVpp65 protein that was established from a patient with GBM [25, 26].  
Materials and Methods  
Flow Cytometry and Reagents 
Surface phenotypes were determined using an Epics XL MCL (Beckman Coulter, CA). The 
following mAbs were purchased from Beckman Coulter: anti-CD3, anti-CD4, anti-CD8, 
anti-Vγ9TCR, anti-CD14, anti-CD25, anti-CD45, anti-CD54, anti-CD56, anti-HLADR, 
anti-CD40, anti-CD80, anti-CD86, anti-CD11c, anti-CD36, mouse IgG1, mouse IgG2, and 
mouse IgG2b mAbs. Anti-HLA-class 1 and anti-CCR7 mAbs were purchased from Beckton 
Dickinson (San Jose, CA) and R & D System (Minneapolis, MN), respectively. Anti-TCR 
Vα24TCR and anti-TCR Vβ11mAbs were purchased from Beckman Coulter (France). 
Anti-human CD273 (PDL2) and CD274 (PDL1) mAbs were purchased form eBioscience 
(CA). Anti-human CD152 (CTLA4) and CD279 (PD1) mAbs were purchased from 
BioLegend (CA). Anti-FoxP3mAb for intracellular staining was purchased from BD 
Biosciences (Japan). All mAbs were conjugated with FITC, PE, APC, ECD, PC5, or PC7. Z 
was purchased from Novartis Pharmaceuticals (Switzerland) and G from Funakoshi Co., Ltd. 
(Japan).  
Generation of IFN-DCs 
PBMCs were isolated from four Pts with GBM and three HDs. HLA-types of these donors 
are listed in Table 1a (Pts) and Table 1b (HDs). All the subjects provided their written 
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informed consent to use their PBMCs for research purpose. For cell culture in this study, 
AIM-V medium (Invitrogen, Japan) containing 10% heat-inactivated human AB serum was 
used. PBMCs separated by density gradient centrifugation with Lymphoprep (Nycomed, 
Norway) were suspended in the medium and then incubated in a flask (Corning Incorporated, 
Japan) for 1 h at 37
o
C. After removing nonadherent cells containing CD8+T cells, Vγ9γδT 
cells, and Vα24NKT cells, monocytes obtained as adherent cells were cultured in the medium 
containing GM-CSF (1000 U/mL; Primmune Inc., Japan) and IFNα (1000 U/mL; INTRON, 
MSD K.K., Japan) for 3 days to obtain IFN-DCs. Alternatively, adherent cells were cultured 
for 5 days in the medium containing GM-CSF (1000 U/mL) and IL-4 (500U /ml) to obtain 
IL-4DCs. The IL-4DCs were further cultured for 2 days in the presence of TNFα (10 ng/mL; 
Reprotech Ltd., UK) to obtain mature IL-4DCs (mIL-4DCs).  
Induction of Tumor Antigen-Specific CD8+T Cells by IFN-DCs  
To investigate MHC-restricted immune responses mediated by CD8+T cells, 
HLA-A*0101-restricted, CMVpp65-modified 11-mer synthetic peptides (YSEHPTFTSQY), 
HLA-A*0201-restricted, CMVpp65-9-mer synthetic peptides (NLVPMVATV), and 
HLA-A*2402-restricted, CMVpp65-9-mer synthetic peptides (VYALPLKML) (Proimmune) 
were used. Lymphocytes (2x10
6
) as a nonadherent cell fraction were cultured with autologous 
IFN-DCs (2x10
5
) under different conditions. IFN-DCs were pulsed with the HLA-A*0101-, 
HLA-A*0201- or HLA-A*2402-restriced P (5μg/mL) for 2 h in serum-free medium and then 
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cultured with the lymphocytes possessing HLA-A*0101, HLA-A*0201, or HLA-A*2402. In 
some experiments, Z (0.1μM) and/or G (100ng/mL) was added during the culture. The 
cultures were supplemented with 50 U/mL IL-2 (Chiron Benelux B. V., The Netherlands) 
during the culture. The percentage of CMVpp65-specific CD8+T cells was assessed using a 
PE-CMVpp65 pentamer (Proimmune) and FITC-anti-CD8 mAb (Beckton Dickinson). 
Cytotoxicity Assay 
T98G tumor cell line was purchased from the American Type Culture Collection (VA, USA). 
Fluorochromasia cell-mediated cytotoxicity assay was carried out using Terascan VPC 
(Minerva Tech, Japan), according to the manufacturer’s instructions. Cells were labeled with 
Calcein-AM solution (Dojindo Laboratories, Kumamoto, Japan) and used as target cells at 
E/T rations of 0.6, 1.3, 2.5, 5, 10, 20, and 40 for 2 h and the cytotoxic activity was evaluated 
by the release of fluorochromasia into the medium (27). 
Statistical Analyses 
The p values for analysis of the expressions of PDL1, PDL2, and CCR7 on DCs were 
calculated using paired/two-tailed Student’s t-test and considered highly significant at <0.01. 
In some cases, the p values for analysis of the expression of CCR7 were calculated using 
Bonferroni’s multiple-comparison test and considered highly significant at <0.01.  
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Results  
Phenotypical Analysis of IFN-DCs Derived from Monocytes as Adherent Cells in the 
Presence of IFNα and GM-CSF 
To characterize surface antigens on IFN-DCs, in comparison with those on mIL-4DCs, 
IFN-DCs and mIL-4DCs were obtained from four Pts with GBM and three HDs. As 
representative results from Pt1, the IFN-DCs showed an almost identical phenotypic pattern 
to mIL-4DCs expressing high levels of HLA-class I, HLA-DR, CD80, CD86, CD40, CD54, 
CD11c, and CD36 (data not shown), but not CD56, CD14, PDL1, PDL2, and CCR7 (Fig. 1a). 
The expression levels of CD56 and CD14 on IFN-DCs from Pts with GBM were significantly 
higher than those on mIL-4DCs (data not shown), as previously reported in the patients with 
various cancers [12, 28]. Phenotypic patterns of IFN-DCs from HDs are very similar to those 
from Pts regarding the expression levels of HLA-class I, HLA-DR, CD80, CD86, CD40, 
CD54, CD11c, CD36, CD56, CD14, PDL1, PDL2, and CCR7 as described previously [28].  
The expression levels of PDL1 and PDL2 which are considered to predominantly mediate 
inhibitory signals towards T cells [29] on IFN-DCs were significantly lower than those on 
mIL-4DCs (Fig. 1b), indicating that IFN-DCs have a higher ability to expand T cells than 
mIL-4DCs. Furthermore, the expression level of lymph node homing receptors, CCR7 on 
IFN-DCs was significantly higher than that on mIL-4DCs (Fig. 1b). The expression level of 
CCR7 on IFN-DCs/P+Z+G was significantly higher than that on IFN-DCs/P (Fig. 1c and 1d). 
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These results suggest that IFN-DCs pulsed with a tumor antigen and Z plus G have a higher 
ability to migrate to the lymph nodes, in comparison with IFN-DCs pulsed with a tumor 
antigen. 
Effective induction of CMVpp65-specific CD8+T cells by IFN-DCs/P+Z+G derived 
from patients with GBM 
The induction of CMVpp65-specific CD8+T cells by autologous IFN-DCs was examined 
under four different conditions: (1) IFN-DCs/P, (2) IFN-DCs/P+Z, (3) IFN-DCs/P+G, and (4) 
IFN-DCs/P+Z+G. In the case of Pt1 possessing HLA-A*0201 and HLA-A*0101, before 
culture each population was shown in Fig. 2a. Before culture, percentages of 
HLA-A*0201-restsricted CMVpp65-specific CD8+T cells and HLA-A*0101-restricted 
CMVpp65-specific CD8+T cells among CD8+T cells were 0.62% and 0.17%, respectively 
and percentages of CD8+T cells, Vγ9γδT cells, and V24NKT cells among lymphocytes 
were 30.00%, 1.71%, and 0.06%, respectively. After culture for 10 days, the results were 
shown in Fig. 2b. Remarkably, IFN-DCs most extensively expanded CMVpp65-specific 
CD8+T cells when pulsed with HLA-A*0201-restricted P and Z plus G, as compared with 
other different conditions mentioned above. In addition, in the case of using IFN-DCs/P+Z+G, 
the expansions of V9T and V24NKT cells were also observed (Fig. 2b). 
To verify our own pentamer results, we assessed the antigen-specific cytotoxic activity of 
lymphocytes containing 51.44% HLA-A*0201-restricted CMVpp65-specific CD8+T cells, 
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12.12% Vγ9γδT cells, and 0.35% Vα24NKT cells with P+Z+G (Fig. 2b with P+Z+G) vs that 
of lymphocytes containing 39.46% HLA-A*0201-restricted CMVpp65-specific CD8+T cells, 
0.10% Vγ9γδT cells, and 0.01% Vα24NKT cells (Fig. 2b with P). Expression levels of MHC 
class 1, PDL1, PDL2, MIC-A which is a ligand for NKG2D on V9T cells, and CD1d 
which is a ligand for V24NKT cells, on T98G tumor cell line used as target cells were 
99.5%, 11.5%, 3.3%, 0.3% and 0.1%, respectively (Fig. 2c) 
As shown in Fig. 2d, the effector cells including CD8+T cells containing 
CMVpp65-specific CD8+T, Vγ9γδT, and Vα24NKT cells (Fig. 2b with P+Z+G) more 
efficiently killed T98G cell line in a dose-dependent manner in comparison with the effector 
cells including mainly CD8+T cell containing CMVpp65-specific CD8+ T cells (Fig. 2b with 
P). This killing activity was not enhanced in the presence of anti-PDL1 and/or 
anti-PDL2mAb presumably owing to the low expression levels of PDL1 and PDL2 on the 
T98G cell line as shown in Fig. 2c. 
Furthermore, we conducted experiments using IFN-DCs from Pt. 1 pulsed with the 
HLA-A*0101-restricted P. The results were similar to those from Pt.1 pulsed with 
HLA-A*0201-restricted P, showing that IFN-DCs most extensively expanded 
CMVpp65-specific CD8+T cells when pulsed with HLA-A*0101-restricted P and Z plus G, 
in addition to the expansions of V9T and V24NKT cells, as compared with other three 
different conditions mentioned above (Fig. 2e). We further conducted experiments using 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
IFN-DCs from another HLA-A*0201 positive Pt. 2 and observed that the percentage of 
HLA-A*0201-restricted CMVpp65-specific CD8+T cells among the expanded CD8+T cells 
expanded by IFN-DCs pulsed with HLA-A*0201-restricted P+Z+G (40.37%) was higher 
than that expanded by IFN-DCs pulsed with P (22.34%). In the cases of another 
HLA-A*0101 positive Pt. 3 using the HLA-A*0101-restricted P, the induction of 
CMVpp65-specific CD8+T cells by IFN-DCs/P+Z+G was also higher than that by 
IFN-DCs/P (21.61% for IFN-DCs/P+Z+G vs 15.43% for IFN-DCs/P). We also tested 
HLA-A*2402 positive Pt. 4 using the HLA-A*2402-restricted peptide. The results showed 
that the induction of CMVpp65-specific CD8+T cells by IFN-DCs/P+Z+G was also higher 
than that by IFN-DCs/P (24.30% for IFN-DCs/P+Z+G vs 14.31% for IFN-DCs/P). Taken 
together, the induction of CMVpp65-specific CD8+T cells by IFN-DCs/P+Z+G was higher 
than that by IFN-DCs/P in all cases using HLA-A*0201-restricted, HLA-A*0101-restricted, 
and HLA-A*2402-restricted P.  Note that remarkable expansion of V9T and V24NKT 
cells were observed in all Pts using IFN-DCs pulsed with P+Z+G. 
For all patients, it was observed that the total number of lymphocytes expanded by 
IFN-DCs/P+Z+G was larger than that expanded by IFN-DCs/P (Table 2: Exp. 1～5). This 
resulted in the higher induction of CMVpp65-specific CD8+T cells in the case of using 
IFN-DCs/P+Z+G, in comparison with the use of IFN-DCs/P (Table 2: Exp. 1～5). Note that 
in the cases of stimulation by IFN-DCs/P+Z+G from Pt. 1, the total number of lymphocytes 
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expanded was larger than those of stimulation by DC under the other three conditions: with 
P, P+Z, and P+G (Table 2: Exp.1 and 2). This provided the highest induction of 
CMVpp65-specific CD8+T cells in the case of using IFN-DCs/P+Z+G. Furthermore, in the 
case of using IFN-DCs/P+Z+G for five experiments from four patients, the number of 
V9T cells among lymphocytes expanded was 8- to 198-fold larger than that in the case of 
using IFN-DCs/P (Table 3). Also the number of V24NKT cells expanded IFN-DCs/P+Z+G 
was larger than that expanded by IFN-DCs/P although the number of that was small in any 
conditions (data not shown). Moreover, the percentage of CD4+CD25+FoxP3+Treg cells 
among lymphocytes following culture with IFN-DCs was examined. The results show that 
the percentage of CD4+CD25+FoxP3+Treg cells among lymphocytes following culture 
with IFN-DCs/P+Z+G was lower than that following culture with IFN-DCs/P in the cases of 
Pts 1, 2, and 4, so far tested (Fig. 3a). Statistical analysis showed that the 
CD4+CD25+FoxP3+Treg cells among lymphocytes following culture with 
IFN-DCs/P+Z+G was significantly lower than the percentage of the Treg cells among 
lymphocytes following culture with IFN-DCs/P (4.22±2.00% vs 5.05±1.93%, p<0.01) 
(Fig. 3b). 
  Immune checkpoint blockade with monoclonal antibodies against the inhibitory immune 
receptors of CTLA4 and PD1 has emerged as a successful treatment approach  
for patients with advanced cancer [30]. Considering the use of a combination of 
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immunotherapies such as DC and CTL- therapy with monoclonal antibodies against CTLA4 
and PD1, we determined the expression levels of PD1 and CTLA4 on CD8+T cells including 
CMVpp65-specific CD8+T cells using IFN-DCs from Pts 1, 2, 3, and 4. Before culture for 
patients, the expression levels of PD1 for four patients and CTLA4 for three patients on 
CD8+T cells were lower than 1% (Fig. 4a). Following culture with IFN-DCs under two 
conditions (with P and with P+Z+G), the expression level of PD1 on CD8+T cells including 
CMVpp65-specific CD8+T cells markedly increased in which the expression level of PD1 on 
CD8+T cells following stimulation by IFN-DCs/P was higher than that following stimulation 
by IFN-DCs/P+Z+G (for Pt. 1, 72.91% vs 65.78%; for Pt. 2, 63.61% vs 40.72%; for Pt. 3, 
61.10% vs 54.74%; for Pt. 4, 77.21% vs 58.31%) (Fig. 4a).  Statistical analysis showed that 
the expression level of PD1 on CD8+T cell following stimulation by IFN-DCs/P+Z+G was 
statistically lower than that following stimulation by IFN-DCs/P (54.89±9.09% vs 68.71±
6.59%, p<0.05) as shown in Fig. 4b. In contrast, the expression level of CTLA4 on CD8+T 
cells including CMVpp65-specific CD8+T cells was less than 3% under the both conditions 
(Fig. 4a). Taken together with these results suggest that among different conditions, 
IFN-DCs/P+Z+G in combination with anti-PD1mab may be able to induce a large number of 
PD1-negative CD8+T cells in vitro and in vivo. 
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Effective induction of CMVpp65-specific CD8+T cells by IFN-DCs/P+Z+G derived 
from HDs 
We further tested the induction ability of CMV-specific CD8+T cells using 
HLA-A*0201-positive IFN-DCs from three HDs. The results are similar to those from the 
patients, that is, the ability of IFN-DCs/P+Z+G to induce CMV-specific CD8+T cells was 
higher than that of IFN-DCs/P [Figs 5a (HD1) and 5b (HD2)]. In the case of HD3, no 
induction of CMV-specific CD8+T cells by IFN-DCs under any conditions was observed, but 
the induction level of Vγ9γδT and Vα24NKT cells did increase in the case of using 
IFN-DCs/P+Z+G (data not shown). It is important to note that for three HDs, the percentage 
of CD4+CD25+FoxP3+Treg cells among lymphocytes following their coculture with 
IFN-DCs/P+Z+G was lower than that following their coculture with IFN-DCs/P (Fig. 5c). 
Similar to the results for Pts as shown in Table 2, the number of CMV-specific CD8+T cells 
expanded by HD-derived IFN-DCs/P+Z+G was larger than those expanded by IFN-DCs/P 
(data not shown). 
Discussion  
  In this study, we demonstrate that IFN-DCs/P+Z+G from Pts with GBM and HDs cross 
talk with CMVpp65-specific CD8+T cells, Z-activated V9T cells, and G-activated 
V24NKT cells in a way that amplifies the activation and prolife ration of  
CMVpp65-specific CD8+T cells. This has a number of important implications, some of 
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which may have a significant impact on the use of Z and G in the setting of cancer therapy 
and represents a best-case scenario for immunotherapies, such as DC and CTL therapies, 
because a large number of tumor antigen-specific T cells may then be available for in vitro 
and in vivo. As noted, the expansion ability of CMVpp65-specific CD8+T cells by IFN-DCs 
pulsed with HLA-A*0201-restricted P and Z plus G was stronger than that by IFN-DCs 
pulsed with HLA-A*0101-restricted P and Z plus G, presumably due to higher frequency of 
HLA-A*0201-restricted CMVpp65-specific CD8+T cells before culture (0.62% for 
HLA-A*0201-restricted vs 0.17% for HLA-A*0101-restricted peptide) as shown in Fig. 2a. 
The use of IFN-DCs in this study had some advantages compared with mIL-4DCs. Our 
results showed that the expression levels of PDL1 and PDL2 on IFN-DCs were significantly 
lower than those on mIL-4DCs (Fig. 1b). This indicates that inhibitory signals from IFN-DCs 
to T cells are weaker than those from mIL-4DCs, which may be associated with the effective 
induction of tumor antigen-specific CD8+T cells by IFN-DCs in vitro and in vivo.  
The expression of CCR7 on DCs is essentially required for DC trafficking from peripheral 
tissues to draining lymph nodes, constituting a central determinant of DC migration and 
function [31].  In this study, IFN-DCs/P+Z+G highly expressed CCR7 [Fig. 1 (c) and (d)]. 
This indicates a high trafficking activity of IFN-DCs/P+Z+G across endothelial cells to 
lymph nodes, where they interact with T cells including antigen-specific CD8+T, V9T and 
V24NKT cells. 
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Current immunotherapies focus on promising a strong anti-tumor T cell response by 
altering the T cells themselves, either by increasing tumor-specific T cells frequency by 
adoptive cell transfer [32] with or without DCs, increasing the reactivity of responding cells 
by engineering of high avidity TCRs specific for tumors [33], or by eliciting more potent T 
cells by blockade of inhibitory costimulatory molecules such as CTLA4 or PD1 [30]. 
Ipilimumab (anti-CTLA4mAb) is the first anticancer agent associated with a documented 
improved overall survival benefit in patients with advanced melanoma. Many tumor 
responses achieved by PD1 and PDL1 inhibition were durable and were seen in a higher 
proportion of patients with melanoma than typically observed with ipilimmab [34].  
Nivolumab was the first mAb targeting PD1 to show significant clinical activity in 
unresectable or metastatic melanoma, non-small-cell lung carcinoma, and metastatic renal 
cell carcinoma [35].  
In this study we confirmed that the expression level of PD1 on CD8+T cells expanded by 
IFN-DCs/P+Z+G was significantly lower than that on CD8+T cells expanded by IFN-DCs/P 
and that the expression level of CTLA4 on CD8+T cells was very low under both conditions 
(Fig. 4a and 4b). Under consideration of DC therapy together with an immunocheckpoint 
blockade, our results suggest that in the case of DC therapy using IFN-DCs/P+Z+G, 
administration of a small amount of anti-PD1mab such as nivolumab, not anti-CTLA4mab 
such as ipilimumab, may result in higher induction of PD1 negative CMV-specific CD8+T 
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cells in vivo. 
   In a previous study, CMV-specific T cells were expanded using PBMCs from patients 
with GBM and infused to the patients [36]. T cells including CMV-specific T cells were 
prepared by culturing PBMC with autologous PBMCs presensitized with the CMV-peptide 
and IL-2. Then, 25 to 40 x10
6 
autologous CMV-specific T cells/infusion were infused. This 
previous study suggests that a combination therapy with autologous CMV-specific T cells and 
chemotherapy is a safe novel treatment and may provide clinical benefits to patients with 
recurrent GBM. Under the consideration of CTL therapy using CMVpp65-specific CD8+T 
cells expanded by IFN-DCs/P+Z+G, more than 30 x 10
6
 of CMVpp65-specific CD8+T cells 
will easily be harvested when 20～30 x 106 lymphocytes are cultured with IFN-DCs/P+Z+G.  
Usually, 36.0±10.3 x 10
6
 lymphocytes are collected from 50 mL of peripheral blood (our own 
observation; n=71). Therefore, it is not difficult to prepare a sufficient number of 
CMV-specific CD8+T cells per injection for patients with GBM, when lymphocytes are 
cultured with IFN-DCs/P+Z+G. Furthermore, in our study using IFN-DCs/P+Z+G, a 500- to 
2700-fold expansion of CMVpp65-specific T cells was completed (Table 2), which is much 
higher than using DCs transfected with CMVpp65-RNA as previously reported [37]. 
  A recent study provides strong evidence supporting the potential of combinatorial targeted 
and/or immunotherapeutic regimens in patients with GBM that may change patient outcome 
[38, 39]. Our results suggest that a combination of immune checkpoint inhibitors, particularly 
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anti-PD1mAb, and DC therapy as well as CTL therapy leads to a better clinical outcome for 
patients with GBM. In the future, the therapeutic pillar of checkpoint blockade will probably 
keep its central role in cancer immunotherapy. Therefore, adaptive immunotherapies such as 
DC therapy and CTL therapy combined with checkpoint blockade will play important roles in 
treatment of cancer patients including GBM patients. 
Identification of the molecular drivers of T cell dysfunction is essential for continued 
progress of cancer research and therapy. Among different immunosuppressive cell 
populations in the TME, Treg cells frequently accumulate in tumor microenvironment and 
even represent the major populations of infiltrating CD4+T cells [22]. Depletion of Treg cells 
or disruption of Treg cell differentiation may restore antitumor T cell responses and immune 
surveillance against cancer. In this study, the induction of CD4+CD25+FoxP3+Treg cells 
among the lymphocytes expanded by IFN-DCs/P+Z+G decreased following stimulation by 
IFN-DCs/P+Z+G in comparison with stimulation by IFN-DCs/P (Fig. 3a and 3b). These 
results indicate that the adjuvant effect of V24NKT and V9T cells may partially 
associated with the decrease in the percentage of CD4+CD25+FoxP3+Treg cells among the 
lymphocytes expanded. Taken together, our results suggest that DC therapy using DCs pulsed 
with tumor antigen and Z plus G is a promising approach, which results in the increase in the 
number of tumor antigen-specific CD8+T cells and in the decrease in that of 
CD4+CD25+FoxP3+ Treg cells although the more precise phenotypical and functional 
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analysis of Treg cells are warranted as shown in the previous study (40). 
In this study, the results of HDs are very similar to those of Pts, showing that a large 
number of CMVpp65-specific CD8+T cells from HDs were harvested following activation of 
lymphocytes with autologous IFN-DCs pulsed with the CMVpp65-peptide and Z plus G in 
vitro. Thus, infusion of the CMVpp65-specific CD8+T cells expanded by IFN-DCs derived 
from allogenic HDs to the patients with hematological malignancy who received alloSCT 
may decrease relapse risk although side effects should be carefully considered. 
The adjuvant effects of a combination of Z-activated Vγ9γδT cells with G-activated 
Vα24NKT cells on antigen-specific CD8+T cells were similar when stimulator IFN-DCs 
were washed to remove extracellular tumor antigens and Z plus G, as when lymphocytes 
were cultured with IFN-DCs pulsed with the tumor antigen and Z plus G. These observations 
support the possible therapeutical applications of IFN-DCs pulsed with a tumor antigen and Z 
plus G. The observed favorable in vitro expansion of CMVpp65-specific CD8+T cells in 
response to DCs with IL-2 indicates that additional, small amounts of exogenous IL-2 may be 
required to maximize the immunotherapeutic benefits of DCs pulsed with a tumor antigen 
and Z plus G in clinical settings.  
Furthermore, it has recently been shown that similarly to DCs, Vγ9γδT cells present 
antigens to  T cells [41, 42]. It is conceivable the Vγ9γδT cells activated in vivo, for 
example, by infused DCs pulsed with a tumor antigen and Z plus G, might play a role as 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
APCs in the uptake of apoptotic bodies from tumor cells. They subsequently induce tumor 
antigen-specific CD8+T cells in vivo in which Vα24NKT cells may function as helper T cells 
producing large amounts of IFNγ, as shown in our previous clinical study [4]. Note that the 
concurrent activation and proliferation of Vγ9γδT cells by Z is MHC-unrestricted [43] and 
that Vα24NKT cells recognize G presented by non-polymorphic CD1d molecules [3]. 
Therefore, the adjuvant effect of the combination of Z and G is theoretically applicable to all 
cancer patients. 
In summary, our study demonstrates the adjuvant effect of a combination of Z and G, 
resulting in the expansions of Vγ9γδT and Vα24NKT cells upon the induction of 
antigen-specific CD8+ T cells using IFN-DCs/P+Z+G. This effect may be a physiologically 
and therapeutically important bridge between innate and adaptive immunities through DCs. 
Our results are consistent with accumulating evidence from clinical and laboratory studies, 
indicating that heterogeneous activation of lymphocytes shapes the responses to vaccination. 
Furthermore, our observations are anticipated to facilitate the design of more effective 
immune therapy strategies, particularly DC therapy combined with immunocheckpoint 
blockades such as anti-PD1 mAbs for patients with GBM.    
AUTHOTSHIP 
Y. E. performed the experiments, analyzed the data and prepared figures, 
H. T. designed the experiments, M.Y. analyzed the data and prepared figures, X. D. designed 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
the experiments, A. N. conceived the study and designed the experiments, M.N. conceived 
the study, performed the experiments, analyzed the data and wrote the manuscript.  
Conflict of Interest 
The authors have declared no conflicting interests. 
References 
1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev 
Immunol 2005; 5:296-306. 
2. Conrad C, Nestle FO. Dendritic cell-based cancer therapy. Curr Opin Mol Ther 2003; 
5:405-12. 
3. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid 
antigens by human natural killer T cells. J Exp Med 1998; 188:1529-34. 
4. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane 
DJ, Nicol AJ. Therapeutic activation of Vα24+Vβ11+NKT cells in human subjects results in 
highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 
103:383-89. 
5. Takahara M, Miyai M, Tomiyama M, Mutou M, Nicol AJ. Nieda M. Copulsing tumor 
antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor 
antigen specific CD8+ T cells via Vγ9γδT cell activation. J of Leukocyte Biology  2008; 
83:742-54.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
6. Castella B, Riganti C, Fior F., Pantaleoni M, Canepari ME, Peola S, Foglietta M, Palumbo 
A, Bosia A, Coscia M, Boccarudo M., Massaia M. Immune Modulation by Zoledronic Acid 
in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2T cells, αβCD8+ T cells, 
Regulatory T cells, and Dendritic Cells. J Immunol 2011; 187:1578-90. 
7. Nestle FO, Alijagic S, Gillet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat 
Med 1998;4:328-32. 
8. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human 
dendritic cells is maintained by granulocyte/machrophage colony-stimulating factor plus 
interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 
1994;179:1109-18. 
9. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. 
Interferon-alpha and granulocyte-machrophage colony-stimulating factor differentiate 
peripheral blood monocytes into potent antigen-presenting cells. J of Leukocyte Biology 
1998; 64:358-67. 
10. Farkas A, Kemeny L. Interferon-α in the generation of monocyte-derived dendritic cells: 
recent advances and implications for dermatology. Br J Dermatol 2011; 165:247-54. 
11. Gruenbacher G, Gander H, Rahm A Nussbaumer W, Romani N, Thurnher M. 
CD56+human blood dendritic cells effectively promote Th1-type γδT cells responses. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Blood 2009; 114:4422-31. 
12. Nieda M, Terunuma H, Eiraku Y, Deng X, Nicol AJ. Effective induction of 
melanoma-antigen-specific CD8+T cells via Vγ9γδT cell expansion by CD56high+ 
interferon--induced dendritic cells. Experimental Dermatology 2015;24:35-41. 
13. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with 
malignant astrocytomas. Ann Neurol 1990;28:818-822. 
14.  Stupp R, Mason WP, van den Bent M J, Weller M, Fisher B, Taphoom MJB, Belanger K, 
Brandes AA, Marosi C, Bogdahn U, Curschman J, Janzer RC, Ludwin SK, Gorlia T, 
Allgeier A, Lacombe D, Cairncross JG , Eisenhauer E, Mirimanoff, RO. Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 
352:987-996. 
15. Prins RM, Cloughesy TF, Liau LM. Induction of Cytomegarovirous-specific Anti-tumor 
Immunity after autologous tumor lysate-pulsed dendritic cell vaccination in a patient with 
glioblasotma. N Engl J Med 2008;359:539-541. 
16.  Sabado RL, Bhardwaj N. Dendritic cell vaccines on the move. Nature 
2015;519:300-301. 
17.  Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King P H, Nabors LB, Britt 
WJ. Human cytomegalovirous infection and expression in human malignant glioma. 
Cancer Res 2002; 62:3347-3350. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
18. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon, RE, Sampson JH. 
(2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of 
patients diagnosed with glioblatoma. Neuro Oncol 2008;10:10-18. 
19. Carreno BM, Collins M. The B7 family of ligands and its receptor: New pathways for 
costimualtion and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53. 
20. Carreno BM, Collins M. BTLA: a new inhibitory receptor with a B7-like ligand. Trends 
Immunol 2003; 24:524-527. 
21. Yamazaki T, Akiba H, Iwai H, Matuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardol 
DM, Okumura K, Azuma M, Yagita H. Expression of programmed death 1 ligands by 
murine T cells and APCs. J Immunol 2002; 169: 5538-5545. 
22. Speise ED, Ho PC, Verdeil H. Regulatory circuits of T cell function in cancer. Nature 
Reviews Immunology 2016;16:599-611. 
23. Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD. Human Dendritic Cells 
Produce TGF-β1 under the influence of lung carcinoma cells and prime the differentiation 
of CD4+CD25+FoxP3+ regulatory T cells. J Immunol 2009;182:2795-2807.  
24. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR,. Zaia J. 
Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known 
challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558. 
25. Ueda R, Ohkusu-Tsukada K, Fusaki N, Soeda A, Kawase T, Kawakami Y, Toda M. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 
expressed in glioma stem cells for immunotherapy. Int J Cancer 2010;126: 919-929. 
26. Min Hua Luo and Elizabeth A. Fortunato. Long term infection and shedding of human 
cytomegalovirus in T98G glioblastoma cells. Journal of Virology. 2007;81: 10424-36 
27. Sasawatari S, Tadaki T, Isogai M., Takahara M., Nieda M., Kakimi K. Efficient priming 
and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC. 
Immunol Cell Biol 2006; 84:512-521. 
28. Nieda M, Terunuma H., Eiraku Y., Deng X., Nicol AJ. Professional expansion of Th1 
type-CD56+V9T cells by CD56+ V9T cells by CD56high+IFNinduced dendritic 
cells derived from cancer patients in vitro and in vivo. International Journal of 
Immunology and Immunotherapy 2015;2:1 
29. Blank C, Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: 
an update on implications for chronic infections and tumor evasion. Cancer Immunol 
Immunother 2007;56:739-745. 
30. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic 
modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 
2013;19:5300-5309. 
31. Worbs T, Hammerschmidt S, Foerster R. Dendritic cell migration in health and disease. 
Nature Review Immunolgy 2017;17:30-48. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
32. Dudly ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwarzentruber DJ, Topalian 
SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, 
Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer 
Regression and autoimmunity in patients with antitumor lymphocytes. Science 
2002;298:850-854 
33. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. 
Trends in Biotechnology 2011;29:1-8. 
34. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, 
Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzkey J, 
Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, 
Clark JI, Wolchok JD, Weber JS, Tian J, Yelline MJ, Nichol GM, Hoos A, Urba WJ. 
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 
2010;363:711-23. 
35. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J 
Clin Invest 2015;125:3384-91. 
36. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, Jones L, Crough T, 
Dasari V, Klein K, Smalley A, Alexander H, Walker DG, Khanna R. Autologous T-cell 
therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. 
Cancer Res 2014;74:3466-76. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
37. Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, Liu R, Johnson LA, 
Weinhold K, Archer GE, Sampson JH, Mitchell DA. Recognition and Killing of 
Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus 
pp65-specific cytotoxic T cells. Clin Cancer Res 2014;20:2684-94. 
38. Shernberg A, Marabelle A, Massard C, Armand JP, Dumont S., Deutsch E, Dhermain F. 
What’s next in glioblastoma treatment: Tumor-targeted or immune targeted therapies? 
Bull Cancer 2016; May; 103 (5):484-98.  
39. Maxwell R, Jackson CM, Lim M, Clinical trials investigating immune checkpoint 
blockade in glioblasotma. Curr Treat Options Oncol. 2017;Aug; 18(8):51.doi: 10. 
1007/s11864-017-0492-y. 
40. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Research 2017; 
27:109-118. 
41. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human 
γδT cells. Science 2005; 309: 264-68. 
42. Muto M, Baghdadi M, Maekawa R, Wada H, Seino K. Myeloid molecular 
characterization of human γδT cells support their acquisition of tumor antigen-presenting 
capacity. Cancer Immunol Immunother 2015;64:941-49. 
43. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic 
non-peptide antigens recognized by human γδT cells. Nature 1995;375:155-58 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1 
HLA-types of donors are listed from four Pts with GBM (a) and three HDs (b). 
Table 1a    Table 1b   
HLA-type of Patients   HLA-type of Healthy Donors 
Pt. 1 HLA-A*0201/A*0101  HD.1 HLA-A*0201/A*2402 
Pt. 2 HLA-A*0201/A*3101  HD.2 HLA-A*0201/A*2402 
Pt. 3 HLA-A*0101   HD.3 HLA-A*0201  
Pt. 4 HLA-A*2402/A*3002     
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Table 2 
Numbers of total lymphocytes and CMVpp65-specific CD8+ T cells following culture with 
IFN-DCs derived from Pts with GBM before culture and after culture under different 
conditions [ with the CMVpp65-peptide alone (P), the peptide with Z (P+Z), the peptide with 
G (P+G), and the peptide and Z plus G (P+Z+G)] .  
 
Patients Peptide used Culture Agents 
No. of 
total lym. 
No. of CMV-specific CD8+T 
A
*
0201 A
*
0101 A
*
2402 
Exp. 1 A
*
0201 Before None 2.0 x 10
6 
 37.2 x 10
2 
 N. T. N. T. 
Pt. 1   After P 14.0 x 106  41.5 x 105  N. T. N. T. 
      P + Z 11.2 x 106  29.2 x 105  N. T. N. T. 
      P + G 10.9 x 106  41.7 x 105  N. T. N. T. 
      P + Z + G 14.1 x 106  53.7 x 105  N. T. N. T. 
Exp. 2 A
*
0101 Before None 2.0 x 10
6 
 N. T. 10.2 x 10
2 
 N. T. 
Pt. 1   After P 6.8 x 106  N. T. 21.5 x 104  N. T. 
      P + Z 9.8 x 106  N. T. 51.7 x 104  N. T. 
      P + G 6.8 x 106  N. T. 19.9 x 104  N. T. 
      P + Z + G 11.5 x 106  N. T. 56.8 x 104  N. T. 
Exp. 3 A
*
0201 Before None 2.0 x 10
6 
 8.2 x 10
2 
 N. T. N. T. 
Pt. 2   After P 9.8 x 106  5.1 x 105  N. T. N. T. 
      P + Z + G 12.4 x 106  22.7 x 105  N. T. N. T. 
Exp. 4 A
*
0101 Before None 2.0 x 10
6 
 N. T. 4.1 x 10
2 
 N. T. 
Pt. 3   After P 7.2 x 106  N. T. 22.4 x 104  N. T. 
      P + Z + G 10.6 x 106  N. T. 67.3 x 104  N. T. 
Exp. 5 A
*
2402 Before None 2.0 x 10
6 
 N. T. N. T. 2.3 x 10
2 
 
Pt. 4   After P 10.1 x 106  N. T. N. T. 35.7 x 104  
      P + Z + G 12.8 x 106  N. T. N. T. 80.5 x 104  
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Table 3 Numbers of total lymphocytes and Vγ9γδT cells following culture with IFN-DCs 
derived from Pts with GBM before culture and after culture under different conditions [with 
the CMVpp65-peptide alone (P) and the peptide and Z plus G (P+Z+G)] 
Patients Peptide used Culture Agents No. of V9T 
Exp. 1 A
*
0201 Before None 3.4 x 10
4
 
Pt. 1   After P 1.4 x 104 
      P + Z + G 170.9 x 104 
Exp. 2 A
*
0101 Before None 3.4 x 10
4
 
Pt. 1   After P 2.2 x 104 
      P + Z + G 437.6 x 10
4
 
Exp. 3 A
*
0201 Before None 3.7 x 10
4
 
Pt. 2   After P 27.8 x 104 
      P + Z + G 232.0 x 104 
Exp. 4 A
*
0101 Before None 4.1 x 10
4
 
Pt. 3   After P 6.1 x 10
4
 
      P + Z + G 406.6 x 104 
Exp. 5 A
*
2402 Before None 4.1 x 10
4
 
Pt. 4   After P 7.5 x 10
4
 
      P + Z + G 462.2 x 104 
 
Figure Legends                                                     
Fig. 1. Phenotypic patterns of IFN-DCs vs mIL-4DCs 
(a) Representative data on phenotypic patterns of CD56, CD14, PDL1, PDL2, and 
CCR7 on IFN-DC and mIL-4DC from Pt. 1 with glioblatoma multiforme (GBM). 
(b) Statistical analysis using of data from four Pts with GBM using paired/two-tailed 
Student’s t-test showed that the percentages of PDL1+ cells and PDL2+ cells among 
IFN-DCs were significantly lower than those among mIL-4DC, and the percentage of CCR7+ 
cells among IFN-DCs was significantly higher than those among mIL-4DCs. 
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(c) The expression level of CCR7 on IFN-DCs from Pt. 1 gradually increased following 
addition of the CMV66-peptide (P) alone, and the addition of the CMVpp65-peptide (P), and 
zoledronate (Z) plus α-galactosyl ceramide (G). 
(d) Statistical analysis of data from four patients with GBM using Bonferroni’s 
multiple-comparison test showed that the percentage of CCR7+ cells among IFN-DCs/P was 
not significantly (n.s.) higher than that among IFN-DCs alone. The percentage of CCR7+ 
cells among IFN-DCs/P+Z+G was significantly higher than that among IFN-DCs alone 
(p<0.005) and was significantly higher than that among IFN-DCs/P (p<0.005). 
 
Fig. 2. Effective induction of CMVpp65-specific CD8+ T cells by IFN-DCs/P+Z+G derived 
from patients with GBM 
 (a) In the case of Pt. 1 possessing HLA-A*0201 and HLA-A*0101, before culture each cell 
population was shown.  
(b) After culture, IFN-DCs from Pt 1 most extensively induced CMVpp65-specific CD8+ T 
cells when pulsed with HLA-A*0201-restricted P and Z plus G in addition to the expansion 
of Vγ9γδT and Vα24NKT cells, in comparison with other three different conditions (P, P+Z, 
and P+G). 
(c) Expression levels of MHC-class I, PDL1, PDL2, MIC-A and CD1d on T98G tumor cell 
line established from a patient with GBM used as target cells were shown. 
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(d) The effector cells including CD8+T cells containing CMVpp65-specific CD8+T, Vγ9γδT 
and Vα24NKT cells (as shown in Fig. 2b with P+Z+G) more efficiently killed the T98G 
tumor cell line in a dose-dependent manner, in comparison with the effector cells including 
mainly CD8+ T cells containing CMVpp65-speccific CD8+T cells (as shown in Fig. 2b with 
P alone). 
(e) After culture, IFN-DCs from Pt. 1 most extensively induced CMVpp65-specific CD8+ T 
cells when pulsed with HLA-A*0101-restricted P and Z plus G, in addition to the expansion 
of V9T and V24NKT cells, in comparison with other three different conditions.(P, P+Z, 
and P+G). 
Fig. 3 (a) The percentage of CD4+CD25+FoxP3+Treg cells among lymphocytes following 
culture with IFN-DCs/P+Z+G from Pts (Pt. 1, Pt. 2, and Pt. 4) was lower than that following 
culture with IFN-DCs/P.  (b) Statistical analysis showed that the percentage of 
CD4+CD25+FoxP3+Treg cells among lymphocytes following culture with IFN-DCs/P+Z+G 
from Patients was significantly lower than the percentage of CD4+CD25+FoxP3+Treg cells 
among lymphocytes following culture with IFN-DCs/P (4.22±2.00% vs 5.05±1.93%, 
p<0.01). 
Fig. 4 The expression levels of PD1 and CTLA4 on CD8+ T cells before culture and after 
culture with Pts (Pts 1, 2, 3 and 4) derived IFN-DCs/P vs Pts derived IFN-DCs/P+Z+G. (a) 
The expression levels of PD1 and CTLA4 on CD8+ T cells including CMVpp65-specific 
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CD8+ T cells before culture were less than 1%. After culture, the expression level of PD1 on 
CD8+ T cells intensively increased, but the expression levels of CTLA4 were less than 2.1% 
under both conditions (IFN-DCs/P and IFN-DCs/P+Z+G). (b) The expression level of PD1 
on CD8+T cells following stimulation by IFN-DCs/P+Z+G was significantly lower than that 
following stimulation by IFN-DCs/P (54.89±9.09% for IFN-DCs/P+Z+G vs 68.71±6.59% 
for IFN-DCs/P; p<0.05). 
Fig. 5 Effective induction of CMVpp65-specific CD8+ T cells by HD-derived 
IFN-DCs/P+Z+G. (a) The ability of IFN-DCs from HLA-A*0201 positive HD1 pulsed with 
HLA-A*0201-restricted P and Z plus G to induce CMV-specific CD8+ T cells was higher 
than that of IFN-DCs/P. In the case of using IFN-DCs/P+Z+G, the expansions of Vγ9γδT and 
Vα24NKT cells were also observed. (b) The ability of IFN-DCs from HLA-A*0201 positive 
HD2 pulsed with HLA-A*0201-restricted P and Z plus G (P+Z+G) to induce CMV-specific 
CD8+T cells was higher than that of IFN-DCs/P. In the case of using IFN-DCs/P+Z+G, the 
expansions of Vγ9γδT and Vα24NKT cells were also observed. (c) The percentage of 
CD4+CD25+FoxP3+Treg cells among lymphocytes from three HLA-A*0201 positive HDs 
(HD1, HD2, and HD3) following their coculture with autologous IFN-DCs pulsed with 
HLA-A*0201-restricted P and Z plus G (P+Z+G) was lower than that following their 
coculture with autologous IFN-DCs/P. 
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